在他的诊疗中，他用禁食（隔日禁食）和减少固体食物来治疗癌症；他本人可以几天不吃东西，只喝甘蔗汁。
原始表述
انا ممكن اقعد بالايام ماكلش اصلا ماكلش يعني ماكلش يعني عصير القصب ده وخلاص انت تعرفي تعملي كده اه تعرفي بس انت مش عايزه تعملي كده انت حره برض لا خلي بالك انا السرطان عندي بعالجه بالصيام بالمناسبه صيام يوم اه يوم لا وقلل في الحاجات الصلبه
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
在他的诊疗中，他用禁食（隔日禁食）和减少固体食物来治疗癌症；他本人可以几天不吃东西，只喝甘蔗汁。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- #الدكتور_ضياء_العوضي (打开来源)
- 发布日期
- 2024年3月8日
- 时间戳
- 0:00:08 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain speech-recognition errors; speaker turns are not marked, the excerpt was judged to be Elawady's own speech from context.
- 所声称的机制
Not stated in the excerpt.
- 所声称的健康影响
Treatment of cancer.
- 涉及人群
Cancer patients treated by him.
- Elawady 设定的地域限制
none found
来源版本存在差异
انا السرطان عندي بجه بالصيام بالمناسبه صيام يوم اه يوم لا وقلل في الحاجات الصلبه
With me, cancer - I treat it with fasting, by the way: fasting one day yes, one day no, and reduce solid foods.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- الجزء الخامس من الندوة (打开来源)
- 发布日期
- 2024年3月3日
- 时间戳
- 0:00:21 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain speech-recognition errors; speaker turns are not marked, the excerpt was judged to be Elawady's own speech from context. Same seminar passage in an earlier upload ('part five of the seminar'); 'بجه' is a transcription variant of 'بعالجه' (I treat it).
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 低 – 进一步研究很可能大幅改变该评估。
1. 说法是什么？
Alternate-day fasting and reducing solid foods are a treatment for cancer.
2. 哪些内容可证实是正确的？
Fasting during cancer therapy is an active research field. In the randomised phase 2 DIRECT trial (131 women with HER2-negative breast cancer, BMI over 18, no diabetes), a fasting-mimicking diet for a few days around each chemotherapy cycle did not improve the primary endpoint (grade III/IV toxicity) or pathological complete response, but was associated with more radiological responses (OR 3.17) and, per protocol, more near-complete pathological responses (OR 4.11) as secondary findings; adherence was poor and the senior author holds equity in the diet's manufacturer (I-INTA-08). A 2025 systematic review found intermittent fasting during chemotherapy safe and feasible under study conditions (I-INTA-10). A 2026 meta-analysis of three small studies found better tumour shrinkage on scans when patients restricted food around chemotherapy (OR 4.55, 1.64-12.58), but without effects on toxicity or quality of life and without survival data; we could not reproduce its pooled estimate (our recalculation 3.50) (I-SRC-109).
3. 哪些内容是错误或夸大的？
These studies tested fasting only as an add-on to chemotherapy, never as a replacement. The systematic review found no demonstrated effect of intermittent fasting on treatment outcomes or toxicity (I-INTA-10). Malnutrition and muscle loss are frequent in cancer patients and worsen outcomes; European guidelines recommend regular malnutrition screening and meeting energy and protein needs (I-INTA-09). Cancer cachexia involves ongoing muscle loss that conventional nutrition cannot fully reverse (I-CAN-06), so repeated fasting and reduced solid food can be harmful. Using alternatives instead of standard treatment is associated with higher mortality (I-CHM-03, I-CHM-04). The ESMO guideline on cancer cachexia recommends nutritional screening and support for all patients on anticancer treatment and at least 25-30 kcal per kg body weight per day (I-SRC-108).
4. 哪些内容仍不明确？
Whether he combined fasting with standard oncology care for his patients is not stated; no outcomes of his patients are documented. Whether short-term fasting improves survival as an adjunct is unknown.
5. 哪些研究支持该说法？
None for fasting as a cancer treatment. I-INTA-08 and I-SRC-109 tested short, supervised dietary restriction only as an add-on to chemotherapy (surrogate endpoints, small studies).
6. 哪些研究与该说法相矛盾？
I-INTA-08 (primary endpoints not improved), I-INTA-10, I-INTA-09, I-SRC-108, I-CAN-06, I-CHM-03, I-CHM-04.
7. 对德国和欧洲而言情况如何？
ESPEN guidelines (I-INTA-09) are the reference in Europe; fasting is not part of standard cancer treatment.
8. 关于埃及的已知情况是什么？
No Egypt-specific data; the same guideline principles apply.
9. 合理的实际结论是什么？
禁食不是癌症治疗方法。化疗期间的短期禁食只应在研究中或与肿瘤治疗团队一起考虑，并且仅适用于没有营养不良的患者。
评估详情
- 证据确定性的依据
No clinical study has tested fasting as a stand-alone cancer treatment; trials of short fasting or fasting-mimicking diets as an adjunct to chemotherapy are few and small, with only secondary/per-protocol signals in one phase 2 trial whose primary endpoints were null and an overall systematic review showing no demonstrated effect on outcomes. Harm from malnutrition and from replacing treatment is well documented. Certainty that fasting 'treats' cancer is therefore low, and the claim is rated mostly false rather than false because adjunct fasting is an open research question.
- 来源质量
Elawady's own words in an archive machine transcript (live stream); exact wording may contain recognition errors. Spoken during a seminar (2024).
- 地区可推广性
High; cancer biology and nutrition guidance are universal.
- 个体例外情况
Short, supervised fasting periods around chemotherapy are being studied in selected, well-nourished patients without diabetes (I-INTA-08).
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: In people with cancer, does alternate-day fasting and reduced solid food intake, used as treatment, improve tumour control or survival compared with standard oncology care with adequate nutrition?
研究问题详解 (PICO)
- 人群
- Adults with cancer
- 干预或暴露
- Alternate-day fasting / reduced solid food as treatment (alone or with standard care)
- 对照
- Standard cancer treatment with nutritional support
- 地域范围
- universal biology
- 结局指标
- Overall survival
- Tumour response
- Toxicity
- Malnutrition/cachexia
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Short fasting alongside cancer treatment
Agrawal K et al.. Cancer Biol Med 2026 · PMID 42444194 · DOI 10.20892/j.issn.2095-3941.2025.0841 Meta分析已核查全文新增2026 meta-analysis of dietary restriction during active cancer therapy (letter; full text read).
- 实际结果
- Favourable radiological response OR 4.55 (1.64-12.58), 3 studies (169 patients); no significant effect on toxicity or quality of life; survival not studied.
- 方法学质量
- low (3 small studies; pooled OR not reproducible: our MH 3.50)
- 相关性
- indirect: adjunct to chemotherapy, not stand-alone treatment
- 局限
- Malnourished patients excluded; surrogate endpoint.
Can short fasting periods help chemotherapy work?
de Groot S et al.. Nature communications 2020 · PMID 32576828 · DOI 10.1038/s41467-020-16138-3 随机对照试验全文，含结构化偏倚风险评估DIRECT phase 2 RCT of a fasting-mimicking diet around neoadjuvant chemotherapy.
- 实际结果
- Primary endpoints (toxicity, pCR) not improved; more radiological responses (OR 3.17) and per-protocol near-complete responses (OR 4.11) as secondary findings.
- 方法学质量
- moderate (RCT, poor adherence)
- 相关性
- indirect: adjunct only
- 局限
- Secondary/per-protocol findings; senior author COI.
哪些证据不支持该说法？
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
NCDB cohort: complementary medicine and refusal of conventional therapy.
- 实际结果
- Complementary-medicine users refused more surgery (7.0% vs 0.1%) and chemotherapy (34.1% vs 3.2%); overall death HR 2.08 (1.50-2.90), which became non-significant (HR 1.39, 0.83-2.33) after adjusting for refusal/delay, i.e. the excess risk was mediated by refusing treatment.
- 方法学质量
- low-moderate (observational)
- 相关性
- direct for replacing treatment
- 局限
- Confounding; not about fasting specifically.
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092 指南 / 立场声明已核查摘要新增ESMO 2021 cancer cachexia guideline.
- 实际结果
- Regular nutritional screening and support for all patients on anticancer therapy; at least 25-30 kcal/kg/day; protein >=1.2 g/kg/day may be needed.
- 方法学质量
- guideline
- 相关性
- direct for nutritional standard
- 局限
- Low evidence levels for some points.
Does intermittent fasting help during chemotherapy?
Maes J et al.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025 · PMID 40970988 · DOI 10.1007/s00520-025-09907-7 系统综述已核查摘要2025 systematic review of intermittent fasting during chemotherapy/targeted therapy.
- 实际结果
- Safe and feasible under study conditions; no demonstrated effect on outcomes or toxicity.
- 方法学质量
- moderate
- 相关性
- direct for adjunct fasting
- 局限
- Small studies.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Fasting is not a cancer treatment; short supervised fasting as an adjunct is an open research question in well-nourished patients.
为什么有些研究权重更大
Guidelines and outcome data on replacing treatment weigh more than surrogate-endpoint signals from three small adjunct studies whose pooled estimate could not be reproduced.
因果关系是否已确立？ 尚未确立 No trial tests fasting as stand-alone treatment; adjunct benefits are unconfirmed on survival.
仍存在的不确定性
Whether short-term fasting improves survival when added to chemotherapy; safety in malnourished patients.
合理的结论
Alternate-day fasting is not an evidence-based cancer treatment and conflicts with guideline nutrition standards; any fasting during therapy belongs in trials or under the oncology team.
为什么研究结果看起来互相矛盾？
Apparent conflict between positive adjunct signals (I-SRC-109, I-INTA-08) and guidelines (I-SRC-108) dissolves on inspection: the trials used short, supervised fasting around chemotherapy in non-malnourished patients and measured tumour response, while guidelines address nutrition across the disease course and malnutrition risk.
这是否取决于国家？
- 一般生物学效应
- Universal.
- 饮食习惯
- Ramadan-type fasting differs from alternate-day fasting during treatment.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable.
- 法律规则
- Not applicable.
- 实际监测数据
- No Egyptian data.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Recompute per-study ORs from Table 1, Mantel-Haenszel pooled OR, CI symmetry – Per-study ORs 3.75, 2.89, 6.18 (continuity-corrected); MH OR 3.50 vs reported fixed 4.80 and random 4.55; reported CIs log-symmetric. Pooled estimate exceeds two of three study ORs and could not be reproduced. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Survival/tumour control with fasting as cancer treatment
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness: only adjunct studies with surrogate endpoints
- imprecision: very few small studies
- risk of bias: open-label, poor adherence
- 结果
- 极低
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ESMO: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines (2021) · 原始文献
Regular nutritional screening and support for patients on anticancer treatment [V, B]; at least 25-30 kcal/kg/day [V, B]; escalate nutritional interventions when intake is inadequate during anticancer therapy [II, A]. - ESPEN: ESPEN practical guideline: Clinical Nutrition in cancer (2021) · 原始文献
Abstract only: 43 recommendations on nutritional and metabolic management of cancer patients, preceded by diagnostics of nutritional status (specific statements not read).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | ("short-term fasting" OR "fasting mimicking" OR "intermittent fasting" OR "alternate day fasting") AND cancer AND (randomized OR randomised) AND (chemotherapy OR survival OR response) AND PUB_YEAR:[2020 TO 2026] | 支持性证据 | 1828 | |
| Europe PMC | 2026年10月26日 | (fasting OR "caloric restriction") AND cancer patients AND (meta-analysis OR "systematic review") AND (survival OR toxicity OR "quality of life") AND PUB_YEAR:[2022 TO 2026] | 双向 | 13348 | |
| PubMed | 2026年10月26日 | ESPEN practical guideline clinical nutrition in cancer | 指南 | 40 | |
| PubMed | 2026年10月26日 | cancer cachexia ESMO clinical practice guideline 2021 | 指南 | 1 | |
| PubMed | 2026年10月26日 | (alternative medicine OR complementary medicine OR "refusal of conventional") AND cancer AND survival AND (cohort OR "National Cancer Database") | 反对性证据 | 2446 |
待解决的问题
Survival effect of supervised fasting as an adjunct; reproduction of the pooled OR.
核查深度如何？
8 项相关研究：2 项核查了全文（其中 1 项进行了结构化偏倚风险评估），6 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
通俗解释
Elawady 医生说，他用隔日禁食和少吃固体食物来治疗癌症。一些小型研究正在测试在化疗的同时进行短期禁食，一项乳腺癌试验显示肿瘤反应更好。但没有研究表明单靠禁食就能治疗癌症，一篇纳入九项研究的综述发现，禁食对治疗结果没有已证实的效果。许多癌症患者体重和肌肉下降，这会使结局变差，因此医生力求确保他们吃得足够。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (7)
-
Does intermittent fasting help during chemotherapy?
Maes J et al.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025 · PMID 40970988 · DOI 10.1007/s00520-025-09907-7系统综述独立交叉核查已核查摘要★ 关键研究Nine small studies found fasting feasible and safe under supervision but showed no proven effect on treatment results or side effects.
No demonstrated effect on treatment outcomes.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Intermittent fasting during cancer therapy
- 研究是如何开展的？
Systematic review
- 研究了多少人、动物或样本？
9 studies, 354 patients
- 实际发现了什么？
Safe and feasible; no demonstrated effect on outcomes
- 观察到的效应有多大？
Not pooled
- 研究结果对日常生活意味着什么？
Fasting is not a proven cancer treatment
- 该研究有哪些局限？
Few small studies
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'treating cancer with fasting'
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Effects of fasting without standard treatment (not studied)
-
What should cancer patients eat?
Arends J et al.. Clinical nutrition (Edinburgh, Scotland) 2017 · PMID 27637832 · DOI 10.1016/j.clnu.2016.07.015指南 / 立场声明独立交叉核查已核查摘要★ 关键研究European guidelines say cancer patients should be screened for malnutrition and should get enough energy and protein.
Guideline aims to meet energy needs and prevent malnutrition in cancer patients.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Nutrition in cancer
- 研究是如何开展的？
Clinical guideline (GRADE)
- 研究了多少人、动物或样本？
Adult cancer patients
- 实际发现了什么？
Malnutrition worsens outcomes; energy needs should be met
- 观察到的效应有多大？
Not applicable
- 研究结果对日常生活意味着什么？
Deliberately eating less is risky for many cancer patients
- 该研究有哪些局限？
Abstract only
- 它对 Elawady 的具体说法说明了什么？
Contradicts fasting as a general cancer treatment
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Effects of short supervised fasting
-
Cancer wasting is caused by the cancer itself
Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7指南 / 立场声明独立交叉核查已核查摘要Experts define cachexia as muscle loss driven by the tumour's effects on metabolism and appetite, not fully reversible by food.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Define cachexia.
- 研究是如何开展的？
Delphi consensus.
- 研究了多少人、动物或样本？
Experts.
- 实际发现了什么？
Definition.
- 研究结果对日常生活意味着什么？
Weight loss in cancer needs medical attention.
- 该研究有哪些局限？
Consensus.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'not dying of cancer'.
- 研究结果是否适用于德国和欧洲？
High.
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145队列研究独立交叉核查已核查摘要★ 关键研究Risk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare AM-only vs conventional treatment.
- 研究是如何开展的？
Matched registry cohort.
- 研究了多少人、动物或样本？
840 matched patients.
- 实际发现了什么？
HR 2.50 for death.
- 观察到的效应有多大？
HR 5.68 breast cancer.
- 研究结果对日常生活意味着什么？
Replacing cancer treatment with alternatives is dangerous.
- 该研究有哪些局限？
Observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts refusing therapy.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Effects of complementary approaches used alongside treatment.
-
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487队列研究独立交叉核查已核查摘要★ 关键研究Users of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Study CM and survival.
- 研究是如何开展的？
Registry cohort.
- 研究了多少人、动物或样本？
258 vs 1,032.
- 实际发现了什么？
HR 2.08; explained by refusal.
- 观察到的效应有多大？
5-y OS 82.2% vs 86.6%.
- 研究结果对日常生活意味着什么？
Diet or other approaches alongside treatment are not the problem; replacing treatment is.
- 该研究有哪些局限？
Observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts refusal advice.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Causal effect of any single CM.
-
Can short fasting periods help chemotherapy work?
de Groot S et al.. Nature communications 2020 · PMID 32576828 · DOI 10.1038/s41467-020-16138-3随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究In 131 women with breast cancer, a fasting-mimicking diet around chemotherapy did not reduce severe side effects or increase complete tumour disappearance (the main outcomes); tumour shrinkage on imaging was more frequent, but this was a secondary result.
Fasting-mimicking diet showed better tumour response as an adjunct to chemotherapy, not as stand-alone treatment.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Fasting-mimicking diet with chemotherapy
- 研究是如何开展的？
Randomised phase 2 trial
- 研究了多少人、动物或样本？
131 women, HER2-negative breast cancer
- 实际发现了什么？
More tumour responses with FMD; no toxicity difference
- 观察到的效应有多大？
pCR 10.8% vs 12.7% (no difference); radiological response OR 3.17 (1.06-9.45); pathological response OR 4.11 (per-protocol)
- 研究结果对日常生活意味着什么？
Fasting may become a supportive tool during chemotherapy, under supervision
- 该研究有哪些局限？
Phase 2; main outcomes not improved; benefit only in secondary and per-protocol analyses; poor adherence; lead author holds equity in the diet's manufacturer
- 它对 Elawady 的具体说法说明了什么？
Supports research on fasting as an add-on, not fasting instead of treatment
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
That fasting alone treats cancer
-
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092指南 / 立场声明独立交叉核查已核查摘要Cancer patients on treatment should be screened for malnutrition and get at least 25-30 kcal per kg body weight per day.
Guideline requires at least 25-30 kcal/kg/day and adequate protein during cancer therapy.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide cachexia care
- 研究是如何开展的？
Guideline
- 研究了多少人、动物或样本？
not applicable
- 实际发现了什么？
Screen and feed adequately; escalate nutrition when intake is low
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Cancer patients need enough food, not fasting regimes
- 该研究有哪些局限？
Low evidence levels for some points
- 它对 Elawady 的具体说法说明了什么？
Contradicts fasting as treatment
- 研究结果是否适用于德国和欧洲？
High
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
Short fasting alongside cancer treatment
Agrawal K et al.. Cancer Biol Med 2026 · PMID 42444194 · DOI 10.20892/j.issn.2095-3941.2025.0841Meta分析独立交叉核查已核查全文★ 关键研究In three small studies, patients who restricted food during chemotherapy had better tumour shrinkage on scans; survival was not studied.
Adjunct restriction during chemotherapy associated with better radiological response in 3 small studies; not a replacement for treatment.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pool studies of dietary restriction during cancer therapy
- 研究是如何开展的？
Systematic review and meta-analysis
- 研究了多少人、动物或样本？
3 studies (169 patients) for response
- 实际发现了什么？
Better radiological response; no clear change in toxicity or quality of life
- 观察到的效应有多大？
OR 4.55 (1.64-12.58), not reproducible (our MH 3.50)
- 研究结果对日常生活意味着什么？
Fasting is being studied only as an add-on to treatment
- 该研究有哪些局限？
Very small evidence base; reporting problems
- 它对 Elawady 的具体说法说明了什么？
Does not support fasting instead of treatment
- 研究结果是否适用于德国和欧洲？
Research setting
- 从该研究中明确不能得出什么结论？
Whether fasting prolongs life or replaces treatment
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
ESPEN guidelines (I-INTA-09) are the reference in Europe; fasting is not part of standard cancer treatment.
埃及
No Egypt-specific data; the same guideline principles apply.
在我的国家适用什么？
一般科学评估
基本错误 禁食可能成为化疗期间的一种辅助手段，但它不是癌症的治疗方法；当它导致营养不良或取代治疗时，可能有害。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Impact of intermittent fasting on patients with cancer undergoing chemotherapy and/or targeted therapies: a systematic review of the literature.. Maes J et al.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025 · PMID 40970988 · DOI 10.1007/s00520-025-09907-7
- ESPEN guidelines on nutrition in cancer patients.. Arends J et al.. Clinical nutrition (Edinburgh, Scotland) 2017 · PMID 27637832 · DOI 10.1016/j.clnu.2016.07.015
- Definition and classification of cancer cachexia: an international consensus.. Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
- Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.. de Groot S et al.. Nature communications 2020 · PMID 32576828 · DOI 10.1038/s41467-020-16138-3
- Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆.. Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092
- Dietary restriction during active cancer therapy is associated with improved treatment response: a systematic review and meta-analysis.. Agrawal K et al.. Cancer Biol Med 2026 · PMID 42444194 · DOI 10.20892/j.issn.2095-3941.2025.0841